Literature DB >> 2180614

Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis.

A Hedman1, G Alván, B Strandvik, A Arvidsson.   

Abstract

The steady-state renal clearance of cefsulodin was studied in 6 patients with cystic fibrosis and 8 healthy controls. The drug was administered by constant rate infusion to obtain 2 values of plasma concentration, 2 and 30 mg/L. As an estimate of the glomerular filtration rate, the renal clearance of inulin was measured simultaneously. The results showed the figures for inulin clearance to be approximately 30% higher in cystic fibrosis patients than in healthy controls at both concentrations, and a corresponding increase in the renal clearance of cefsulodin was seen in patients over controls. The ratio between the renal clearances of the 2 substances was on average 0.9 in both groups. The correlation found between the 2 renal clearances (r = 0.75; p less than 0.001) indicates that glomerular filtration rate has considerable influence on the renal elimination of cefsulodin. This finding emphasises the importance of glomerular filtration rate for the renal clearance of drugs in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180614     DOI: 10.2165/00003088-199018020-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  24 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect.

Authors:  J Carlstedt-Duke; M Brönnegård; B Strandvik
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 3.  The molecular and biochemical basis of cystic fibrosis.

Authors:  M A McPherson; R L Dormer
Journal:  Biosci Rep       Date:  1987-03       Impact factor: 3.840

4.  Aminoglycoside clearance in patients with cystic fibrosis.

Authors:  E Finkelstein; K Hall
Journal:  J Pediatr       Date:  1979-01       Impact factor: 4.406

Review 5.  A functional role for the tubuloglomerular feedback mechanism.

Authors:  R C Blantz; J C Pelayo
Journal:  Kidney Int       Date:  1984-05       Impact factor: 10.612

6.  Ceftazidime disposition in acute and stable cystic fibrosis.

Authors:  J S Leeder; M Spino; A F Isles; A M Tesoro; R Gold; S M MacLeod
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

7.  Cloxacillin absorption and disposition in cystic fibrosis.

Authors:  M Spino; R P Chai; A F Isles; J J Thiessen; A Tesoro; R Gold; S M MacLeod
Journal:  J Pediatr       Date:  1984-11       Impact factor: 4.406

8.  Cefsulodin pharmacokinetics in patients with various degrees of renal function.

Authors:  G R Matzke; W F Keane
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

9.  Renal function in patients with cystic fibrosis.

Authors:  M Aladjem; D Lotan; H Boichis; S Orda; D Katznelson
Journal:  Nephron       Date:  1983       Impact factor: 2.847

10.  Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection.

Authors:  G R Granneman; L T Sennello; R C Sonders; B Wynne; E W Thomas
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

View more
  10 in total

Review 1.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

2.  Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm.

Authors:  D J Touw; A A Vinks; C Neef
Journal:  Pharm World Sci       Date:  1997-06

Review 3.  Implications of augmented renal clearance in critically ill patients.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Nat Rev Nephrol       Date:  2011-07-19       Impact factor: 28.314

4.  Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.

Authors:  Mehdi El Hassani; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-01-15       Impact factor: 6.447

5.  Renal function in pediatric cystic fibrosis patients in the first decade of life.

Authors:  Chanel Prestidge; Mark A Chilvers; A George F Davidson; Eva Cho; Vanessa McMahon; Colin T White
Journal:  Pediatr Nephrol       Date:  2010-12-29       Impact factor: 3.714

6.  Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?

Authors:  Miki Susanto; Leslie Z Benet
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

Review 7.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

8.  Prediction of Human Glomerular Filtration Rate from Preterm Neonates to Adults: Evaluation of Predictive Performance of Several Empirical Models.

Authors:  Iftekhar Mahmood; Carl-Michael Staschen
Journal:  AAPS J       Date:  2016-01-22       Impact factor: 4.009

9.  Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.

Authors:  B A Christensson; I Nilsson-Ehle; B Ljungberg; A Lindblad; A S Malmborg; L Hjelte; B Strandvik
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 10.  Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Authors:  Jürgen B Bulitta; Yuanyuan Jiao; Stefanie K Drescher; Antonio Oliver; Arnold Louie; Bartolome Moya; Xun Tao; Mathias Wittau; Brian T Tsuji; Alexandre P Zavascki; Beom Soo Shin; George L Drusano; Fritz Sörgel; Cornelia B Landersdorfer
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.